Stock Quote

05/24/2019 16:00:00
(Minimum 20 minutes delay)

About CSI

We are devoted to developing innovative solutions for treating peripheral and coronary artery disease, to help physicians conquer calcium, one of the largest challenges when treating PAD and CAD and help patients get back to what matters.

Read about our company policies, monitoring, public disclosures and other details.

Healthcare Economics & Outcomes Research

A commitment to leadership

At CSI, we’re on a mission to improve healthcare access and care for coronary artery disease (CAD) and peripheral artery disease (PAD). We’re on a mission to educate patients and physicians. We’re on a mission to improve access and patient outcomes and to deliver value. We collaborate with providers and policy makers to help ensure fair and accurate reimbursement for treatment.

We support groundbreaking research as well as its subsequent publication and presentation to the healthcare community. CSI leaders present at the International Society for Pharmacoeonomics and Outcomes Research (ISPOR) each year.

CSI is a proud supporter of the CardioVascular Coalition, and we continually seek out like-minded industry groups to advance CAD and PAD treatment.

Improving PCI Outcomes for Patients with Complex CAD

At CSI, we’re dedicated to helping reduce severe arterial calcium and enable successful stent delivery to help optimize stent expansion and PCI outcomes. Much of the research surrounding endovascular treatments for CAD exclude patients with severely calcified lesions.

At CSI, we’re focused on developing solutions for this difficult-to-treat population and studying the effectiveness and patient outcomes using orbital atherectomy technology.

Leading the Way for Racial Healthcare Equity in PAD

Peripheral artery disease (PAD) affects up to 18 million people in the US, according to estimates.22 And the numbers will continue to increase:

Some studies suggest that African-Americans may not feel the symptoms as early as Caucasians, therefore they do not seek treatment as early.34

CSI seeks to identify racial and ethnic disparities in PAD treatment through our dedicated research and legislative advocacy efforts.

African-Americans & Hispanics are 2X as likely to be amputated as Caucasians29

HEOR PAD-related Amputations By Race | amCharts

Analysis of amputation rates for the treatment of patients with a primary diagnosis of PAD, using the Healthcare Cost and Utilization Project (HCUP) inpatient database from 2006-2013.

CSI’s Dedication to Research

Clinical research supports our goal of informing health policy. We seek to understand the disease state and patient factors. We find ways to help save limbs and advocate for better access to care in the African-American, Hispanic and Native American communities.

Important findings of our recent research determine that:

African-Americans are twice as likely and Hispanics are 50% more likely to be amputated than Caucasians as a result of advanced PAD28

Results suggest African-Americans and Hispanics have less access to care because they are being admitted when sicker and more likely on an emergent basis28

Caucasians were generally older (average age 70.3 vs. 67.8), wealthier, had less severe diseases and a lower mortality risk than African-Americans or Hispanics28

African-Americans have an average number of 1,503 PAD-related amputations per year29

The amputation rate per minority translates into aggregate healthcare costs of up to $1.12 billion29

2014

2015

2016

• Worked with CMS on Mandated Screening Strategy

2017

• Worked with Congress on PAD Medicare Coverage Legislation

A CardioVascular Coalition Charter Member

The CardioVascular Coalition (CVC) understands that PAD is a leading and preventable cause of death in the US. CSI – along with national physician, provider and advocacy organizations – created the CVC to improve the awareness of and prevention of PAD.

As a coalition, we will secure patient access to high-quality, cost-effective interventional treatment for PAD. To help achieve this goal, the CVC currently operates 211 CardioVascular Centers in 31 states.

States with CardioVascular Centers

Supporting Value-based Technology

The CSI team is committed to assisting healthcare policymakers and healthcare providers in evaluating the economic impact of utilizing orbital atherectomy technology. Our team can provide the background and resources you need to evaluate procedures.

Professional Education

CSIQ is the official medical education program of Cardiovascular Systems, Inc. Our goal is for you to use this information to better understand the prevalence of arterial calcium and how to treat it using our Orbital Atherectomy Systems. From group courses taught by leading orbital atherectomy experts to personalized, one-on-one proctorships, CSIQ demonstrates the value and procedural efficiency of our Orbital Atherectomy Systems. Clinical data that underscore the safety, efficacy and long-term durability of the devices is also provided.

In July 2018, Cardiovascular Systems, Inc. (CSI®) announced that OrbusNeich Medical Co. Ltd. signed an exclusive distribution agreement to sell its coronary and peripheral Orbital Atherectomy Systems outside the United States and Japan.

In November 2016, Cardiovascular Systems, Inc. (CSI®) announced that Medikit, Co., Ltd. signed an exclusive distribution agreement to sell its coronary and peripheral Orbital Atherectomy Systems in Japan.

Smart Solutions that advance treatment for complex patients

At CSI, weare a culture of innovation.
We observe carefully, listen closely and collaborate extensively,
seeking opportunities to help interventionalists do their jobs more easily and more effectively –
all with the goal of improving patient care.